Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are covering the company, Marketbeat reports. Two analysts have rated the ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...

Access to adequate coverage and reimbursement for SCS procedures using Senza by third-party payors is essential to customers' acceptance of Nevro’s products. A significant number of negative ...

Emerging treatment therapies targeting conditions earlier in the care continuum have been impacting demand for Nevro’s prized SCS portfolio. The company’s own SI offerings are solutions for ...

Access to adequate coverage and reimbursement for SCS procedures using Senza by third-party payors is essential to customers' acceptance of Nevro’s products. A significant number of negative ...